Amarin (AMRN) vs SIGA Technologies (SIGA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Amarin (AMRN) has outperformed SIGA Technologies (SIGA) over the past year, losing 37.8% versus a loss of 60.4%. Over five years, SIGA leads with a -53.9% price change compared with -88.4% for AMRN. Amarin is the larger company by market cap ($256.1 million vs $235.3 million), about 1.1 times the size.
On valuation, SIGA Technologies trades at a lower forward P/E (3.0x vs 12.4x for Amarin).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRN | SIGA |
|---|---|---|
| Share price | $12.13 | $3.28 |
| Market cap | $256.11M | $235.31M |
| 1-day change | +1.13% | -0.15% |
| YTD return | -14.11% | -46.32% |
| 1-year return | -37.81% | -60.39% |
| 5-year return | -88.38% | -53.87% |
| Forward P/E | 12.37 | 3.03 |
| EPS (TTM) | $-1.20 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.90 | $8.55 |
| 52-week low | $11.83 | $2.83 |
| Distance from 52-week high | -41.99% | -61.70% |
| Analyst consensus | none | none |
| Avg. price target upside | +3.09% | — |
| Average volume | 66.23K | 726.75K |
| Shares outstanding | 21.12M | 71.85M |
| Employees | 80 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMRN has outperformed SIGA by 22.6 percentage points over the past year.
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About SIGA Technologies
SIGA stock →SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
AMRN vs SIGA FAQ
Which is bigger, Amarin or SIGA Technologies?
Amarin (AMRN) is larger, with a market capitalization of $256.11M compared with $235.31M for SIGA Technologies (SIGA).
Which stock has performed better over the past year, AMRN or SIGA?
AMRN returned -37.81% over the past 12 months, compared with -60.39% for SIGA (price return, excluding dividends). Past performance does not predict future results.
Are Amarin and SIGA Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.